Literature DB >> 33484332

Eosinophilic fasciitis in a pregnant woman with corticosteroid dependence and good response to infliximab.

Nicolás Jiménez-García1, Josefa Aguilar-García2, Inés Fernández-Canedo3, Nuria Blázquez-Sánchez3, Rafael Fúnez-Liébana4, Carlos Romero-Gómez5.   

Abstract

Eosinophilic fasciitis (EF) is characterized by symmetrical thickening of subcutaneous muscular fascia, causing skin induration with wrinkles and prominent hair follicles: the classic peau d'orange. Eosinophilia is a characteristic-albeit not universal-finding. We present the case of a 43-year-old pregnant woman diagnosed with EF during pregnancy who had extensive cutaneous involvement and severe functional repercussions, including worsening of lung function and intrauterine growth restriction as a possible complication. Treatment with prednisone was initiated during gestation and it was necessary to increase the dose. After delivery, methotrexate treatment was initiated and the corticosteroid dose progressively decreased, with progressive worsening in the torso and abdomen and secondary dyspnea due to thoracic pressure. Treatment with infliximab was then initiated, with favorable progress, though residual ankle and tarsal joint stiffness and significant muscular atrophy in the limbs continued. The triggering factor of EF was not identified. In a systematic search of the medical literature, three cases of EF in pregnant woman without clear triggers were found. Interestingly, all three cases progressed favorably with steroid treatment. Apart from this case, there are only seven published cases of infliximab use in the literature, all with moderate or complete response. Infliximab could be an option for corticosteroid-dependent EF with no response to other options.

Entities:  

Keywords:  Corticosteroid dependence; Eosinophilic fasciitis; Infliximab; Intrauterine growth restriction; Methotrexate; Pregnancy

Mesh:

Substances:

Year:  2021        PMID: 33484332     DOI: 10.1007/s00296-021-04787-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  48 in total

1.  Proceedings: Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome.

Authors:  G P Rodnan; A DiBartolomeo; T A Medsger
Journal:  Arthritis Rheum       Date:  1975 Sep-Oct

2.  Diffuse fasciitis with eosinophilia: a new syndrome?

Authors:  L E Shulman
Journal:  Trans Assoc Am Physicians       Date:  1975

3.  Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients.

Authors:  Jorre S Mertens; Rogier M Thurlings; Wietske Kievit; Marieke M B Seyger; Timothy R D Radstake; Elke M G J de Jong
Journal:  J Am Acad Dermatol       Date:  2017-07-19       Impact factor: 11.527

4.  Eosinophilic fasciitis following pregnancy.

Authors:  J M Strosberg
Journal:  JAMA       Date:  1979-05-18       Impact factor: 56.272

Review 5.  Eosinophilic fasciitis: From pathophysiology to treatment.

Authors:  Hironobu Ihn
Journal:  Allergol Int       Date:  2019-03-22       Impact factor: 5.836

6.  Eosinophilic fasciitis during pregnancy.

Authors:  H S Amdur; R E Levin
Journal:  Obstet Gynecol       Date:  1989-05       Impact factor: 7.661

7.  Eosinophilic fasciitis. Review and report of six cases.

Authors:  V A Nassonova; M M Ivanova; V D Akhnazarova; T G Oskilko; A Bjelle; P A Hofer; K G Henriksson; T Ström
Journal:  Scand J Rheumatol       Date:  1979       Impact factor: 3.641

Review 8.  Diagnosis and classification of eosinophilic fasciitis.

Authors:  I Pinal-Fernandez; A Selva-O' Callaghan; J M Grau
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

9.  Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases.

Authors:  S Lakhanpal; W W Ginsburg; C J Michet; J A Doyle; S B Moore
Journal:  Semin Arthritis Rheum       Date:  1988-05       Impact factor: 5.532

Review 10.  Eosinophilic fasciitis during pregnancy: case report and review of literature.

Authors:  Maria Ester Simeira Fonseca; Maria Victória Quaresma; Ana Paula Luppino-Assad; Henrique Carriço da Silva; Danieli Castro O Andrade; Percival D Sampaio-Barros
Journal:  Rheumatol Int       Date:  2017-12-15       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.